Profile data is unavailable for this security.
About the company
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.
- Revenue in USD (TTM)64.00k
- Net income in USD-165.29m
- Incorporated2010
- Employees233.00
- LocationSeres Therapeutics Inc101 Cambridge Park DriveCAMBRIDGE 02140United StatesUSA
- Phone+1 (617) 945-9626
- Fax+1 (302) 655-5049
- Websitehttps://www.serestherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverum Biotechnologies Inc | 1.00m | -94.11m | 119.61m | 121.00 | -- | 0.8299 | -- | 119.61 | -6.03 | -6.03 | 0.0585 | 6.93 | 0.0046 | -- | -- | 8,264.46 | -43.66 | -36.39 | -50.24 | -39.04 | -- | -- | -9,411.10 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 121.35m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -152.52m | 122.33m | 75.00 | -- | 0.4386 | -- | -- | -2.37 | -2.37 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -48.98 | -- | -52.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.60m | 122.64m | 66.00 | -- | 1.34 | -- | -- | -2.07 | -2.07 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -56.88 | -- | -66.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Cidara Therapeutics Inc | 18.86m | -123.53m | 122.96m | 69.00 | -- | 1.06 | -- | 6.52 | -26.06 | -25.94 | 3.74 | 16.41 | 0.167 | -- | 8.28 | 273,304.30 | -109.42 | -65.23 | -169.41 | -154.37 | 87.21 | -- | -655.07 | -100.61 | -- | -- | 0.0055 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Seres Therapeutics Inc | 64.00k | -165.29m | 124.55m | 233.00 | -- | 5.21 | -- | 1,946.13 | -1.14 | -0.2271 | 0.0004 | 0.1405 | 0.0002 | -- | -- | 274.68 | -60.50 | -41.51 | -82.15 | -54.13 | -- | -- | -258,259.40 | -170.14 | -- | -20.45 | 0.00 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Pyxis Oncology Inc | 16.15m | -57.36m | 124.88m | 54.00 | -- | 0.8124 | -- | 7.73 | -1.05 | -1.05 | 0.2977 | 2.59 | 0.0845 | -- | -- | 322,920.00 | -30.03 | -- | -34.41 | -- | 97.06 | -- | -355.24 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Repare Therapeutics Inc | 66.52m | -84.05m | 126.26m | 179.00 | -- | 0.7216 | -- | 1.90 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Skye Bioscience Inc | 0.00 | -21.24m | 126.51m | 11.00 | -- | 1.67 | -- | -- | -0.8405 | -0.8405 | 0.00 | 2.50 | 0.00 | -- | -- | 0.00 | -43.73 | -232.67 | -54.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Coherus Biosciences Inc | 304.34m | -450.00k | 126.73m | 235.00 | -- | -- | 26.10 | 0.4164 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Cardiff Oncology Inc | 689.00k | -43.01m | 127.83m | 31.00 | -- | 2.47 | -- | 185.54 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Fennec Pharmaceuticals Inc | 49.35m | -1.13m | 129.48m | 36.00 | -- | -- | -- | 2.62 | -0.1004 | -0.1004 | 1.75 | -0.1886 | 1.27 | 2.22 | 5.66 | -- | -2.91 | -73.43 | -3.40 | -84.32 | 93.52 | -- | -2.30 | -383.28 | 7.64 | 0.5978 | 1.21 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| TriSalus Life Sciences Inc | 26.89m | -58.65m | 129.85m | 112.00 | -- | -- | -- | 4.83 | -1.68 | -1.68 | 0.8963 | -0.6706 | 0.8812 | 1.23 | 6.75 | 240,098.20 | -181.70 | -- | -265.24 | -- | 87.10 | -- | -206.19 | -- | 2.00 | -26.43 | 17.43 | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Seres Therapeutics Inc's reporting currency: US Dollar USD
21.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 22.86m | 13.43% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 6.02m | 3.54% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.68m | 0.99% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.39m | 0.82% |
| Susquehanna Financial Group LLLPas of 30 Sep 2024 | 1.18m | 0.70% |
| Millennium Management LLCas of 30 Sep 2024 | 1.02m | 0.60% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 756.70k | 0.45% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2024 | 748.72k | 0.44% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2024 | 433.90k | 0.26% |
| Bank Vontobel AGas of 30 Sep 2024 | 394.83k | 0.23% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
